Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Institute of Biomedi (MRES)

Institute of Biomedi (MRES)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
RLAB & MRES: Tiago Henriques Joins M2MMA Combat Sports Promotion Advisory Board

DUBAI, UAE / ACCESS Newswire / January 24, 2025 / Real American Capital Corp (OTC PINK:RLAB), trading as M2MMA, is an avant-garde powerhouse reshaping the combat sports landscape. It is thrilled to announce...

MRES : 0.0035 (-46.97%)
RLAB : 8.0720 (+0.90%)
MRES: Dr. Esmarilda Dankaert Appointed Chief Innovation Officer (CINO) at M2Bio Sciences

DUBAI, UAE / ACCESSWIRE / November 25, 2024 / The Institute of Biomedical Research Corp. (OTC PINK:MRES), operating as M2Bio Sciences, is a pioneering biotechnology company dedicated to advancing health...

MRES : 0.0035 (-46.97%)
MRES: Institute of Biomedical Research unveils artificial intelligence (AI) powered initiatives within its CBD product range, psilocybin research, and cardiometabolic health solutions

/PRNewswire/ -- Institute of Biomedical Research Corp. (OTC-PINK: MRES) ("Institute of Biomedical Research" or the "Company"), a nutraceutical biotechnology...

MRES : 0.0035 (-46.97%)

Barchart Exclusives

The Most Overlooked Dividend Kings to Buy in 2026
These overlooked Dividend Kings offer accelerating dividend growth, improving profitability, and long-term bullish momentum that income investors can rely on for consistent returns in 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar